Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | PRKDC | P78527 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12643176 | 0.89 | MAPT (0.74) | MAPTALDH1A1SMN1; SMN2NPSR1LMNA | |
| SCHEMBL9515788 | 0.87 | MAPT (0.63) | MAPTALDH1A1SMN1; SMN2NPSR1LMNA | |
| SCHEMBL5098517 | 0.86 | ALDH1A1 (0.62) | MAPTALDH1A1SMN1; SMN2NPSR1LMNA | |
| SCHEMBL6377084 | 0.85 | LMNA (0.58) | MAPTALDH1A1SMN1; SMN2NPSR1LMNA | |
| SCHEMBL26086358 | 0.85 | MAPT (0.53) | MAPTALDH1A1SMN1; SMN2NPSR1LMNA | |
| SCHEMBL30396635 | 0.85 | MAPT (0.53) | MAPTALDH1A1SMN1; SMN2NPSR1LMNA | |
| SCHEMBL22471070 | 0.84 | ALDH1A1 (0.61) | MAPTALDH1A1SMN1; SMN2LMNACYP2C9 | |
| SCHEMBL22471135 | 0.83 | MAPT (0.60) | MAPTALDH1A1SMN1; SMN2LMNAMAPK1 | |
| SCHEMBL22470988 | 0.83 | MAPT (0.50) | MAPTALDH1A1SMN1; SMN2LMNAHPGD | |
| SCHEMBL19030353 | 0.81 | MAPT (0.59) | MAPTALDH1A1SMN1; SMN2NPSR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111315742-B | Process for preparing aminopyrimidine derivatives | 株式会社 柳韩洋行 | 2023-09-01 | — | — | CN | disclosed |
| WO-2022199589-A1 | PYRIMIDINE DERIVATIVES | 南京明德新药研发有限公司 | 2022-09-29 | — | — | WO | disclosed |
| US-20220041569-A1 | (3aS,4aR,5S,7aS,9R,9aR)-2,2,5,8,8,9a-hexamethyloctahydro-4H-4a,9-methanoazuleno[5,6-d][1,3]dioxole | GIVAUDAN S.A. (CH) | 2022-02-10 | — | — | US | disclosed |
| CN-111356687-B | Pyrimidine-containing tri-substituted imidazole compound and application thereof | 广州必贝特医药技术有限公司 | 2021-03-30 | — | — | CN | disclosed |
| WO-2020192302-A1 | PYRIMIDINE-CONTAINING TRI-SUBSTITUTED IMIDAZOLE COMPOUND AND APPLICATION THEREOF | 广州必贝特医药技术有限公司 | 2020-10-01 | — | — | WO | disclosed |
| CN-111356687-A | Pyrimidine-containing tri-substituted imidazole compound and application thereof | 广州必贝特医药技术有限公司 | 2020-06-30 | — | — | CN | disclosed |
| EP-2684874-B1 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors | CEPHALON INC (US) | 2017-05-17 | — | — | EP | disclosed |
| EP-2222647-B1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON INC (US) | 2015-08-05 | — | — | EP | disclosed |
| EP-2684874-A1 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors | Cephalon, Inc. (US) | 2014-01-15 | — | — | EP | disclosed |
| US-8552186-B2 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-MET inhibitors | CEPHALON, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20120165519-A1 | Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors | CEPHALON, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-8148391-B2 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors | CEPHALON, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| EP-2222647-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | Cephalon, Inc. (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | CEPHALON, INC. (US) | 2009-09-03 | — | — | US | disclosed |
| WO-2008051547-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| US-4749648-A | Agent for the determination of esterolytic and/or proteolytic enzymes | BOEHRINGER MANNHEIM GMBH (DE) | 1988-06-07 | — | — | US | disclosed |
| EP-0039880-B2 | AGENTS FOR THE DETECTION OF ESTEROLYTIC AND/OR PROTEOLYTIC ENZYMES; AND PHENOXY-AMINO ACIDS AND PHENOXY-PEPTIDE ESTERS SUITABLE AS SUBSTRATES THEREFOR, PROCESS FOR THEIR PRODUCTION AND THEIR USE IN PRODUCING THE AGENTS | Roche Diagnostics GmbH (DE) | 1987-06-03 | — | — | EP | disclosed |
| US-4551428-A | COLORIMETRIC ANALYSIS USING DIAZONIUM COUPLERS | BOEHRINGER MANNHEIM GMBH (DE) | 1985-11-05 | — | — | US | disclosed |
| EP-0039880-B1 | AGENTS FOR THE DETECTION OF ESTEROLYTIC AND/OR PROTEOLYTIC ENZYMES; AND PHENOXY-AMINO ACIDS AND PHENOXY-PEPTIDE ESTERS SUITABLE AS SUBSTRATES THEREFOR, PROCESS FOR THEIR PRODUCTION AND THEIR USE IN PRODUCING THE AGENTS | Roche Diagnostics GmbH (DE) | 1983-06-29 | — | — | EP | disclosed |
| EP-0039880-A1 | Agents for the detection of esterolytic and/or proteolytic enzymes; and phenoxy-amino acids and phenoxy-peptide esters suitable as substrates therefor, process for their production and their use in producing the agents | Roche Diagnostics GmbH (DE) | 1981-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | ALK, MET, RET | MAPT 3881/4885ALDH1A1 77/4885SMN1; SMN2 2836/4885 |
| US-20220041569-A1 | (3aS,4aR,5S,7aS,9R,9aR)-2,2,5,8,8,9a-hexamethyloctahydro-4H-4a,9-methanoazuleno[5,6-d][1,3]dioxole | DHRS9, MSMO1, CYP4X1 | MAPT 3264/4885ALDH1A1 669/4885SMN1; SMN2 2451/4885 |
| US-20120165519-A1 | Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors | ALK, MET, RET | MAPT 3881/4885ALDH1A1 77/4885SMN1; SMN2 2836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.